Spherix Diabetes Drug Meets Midstage Dtudy Goal
Wed, 06/24/2009 - 12:48pm
BETHESDA, Md. (AP) — Spherix Inc. said Wednesday its developing diabetes treatment Naturlose met its key goal of reducing glucose levels in patients. The midstage, or Phase II, clinical trial tested doses ranging from 2.5 grams to 7.5 grams. Full study results are expected to be complete in early 2010. The company has a larger late-stage, or Phase III, study testing a 15-gram dose.